WO2011043220A1 - 融合遺伝子の測定方法 - Google Patents
融合遺伝子の測定方法 Download PDFInfo
- Publication number
- WO2011043220A1 WO2011043220A1 PCT/JP2010/066768 JP2010066768W WO2011043220A1 WO 2011043220 A1 WO2011043220 A1 WO 2011043220A1 JP 2010066768 W JP2010066768 W JP 2010066768W WO 2011043220 A1 WO2011043220 A1 WO 2011043220A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- region
- gene
- fusion
- seq
- alk
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Definitions
- the present invention relates to a method for measuring a fusion gene that may exist in a living body.
- the fusion gene is known to cause cancer.
- an undifferentiated lymphoma kinase (Anaplastic Lymphoma Kinase; ⁇ ⁇ ⁇ ALK) gene, which is one of receptor tyrosine kinases, exhibits carcinogenicity by fusing with various genes (Non-patent Document 5). .
- the EML4-ALK fusion gene is a gene in which a part of the 5 'side of the Echinoderm Microtubule-associated protein-Like 4 (EML4) gene and the 3' region of the ALK gene are fused. It is known to cause some non-small cell lung cancer (Patent Document 1, Non-Patent Document 1). As a method for detecting an EML4-ALK fusion gene, a method of amplifying EML4-ALK fusion gene mRNA by RT-PCR method has been reported (Non-patent Document 2).
- an object of the present invention is to provide a simple fusion gene detection system that can cover even unknown fusion genes.
- the inventor of the present application pays attention to the fact that the essence of the EML4-ALK fusion gene is “X (arbitrary gene) + ALK gene 3 ′ region (including kinase domain)”, and the fusion point is the boundary.
- X arbitrary gene
- ALK gene 3 ′ region including kinase domain
- the present invention is a method performed on a sample separated from a living body, and for one gene constituting a fusion gene that may exist in the living body, a 5 ′ region upstream of the fusion point of the gene and Provided is a method for measuring a fusion gene, comprising measuring the expression of a downstream 3 ′ region and comparing the expression of a 5 ′ region with the expression of a 3 ′ region.
- the present invention also provides a 5 ′ region detection primer set consisting of the base sequences shown in SEQ ID NOs: 3 and 4 of the sequence listing, and a 3 ′ region detection primer consisting of the base sequences shown in SEQ ID NOs: 5 and 6, respectively.
- the present invention provides a 5 ′ region detection primer set consisting of the base sequences shown in SEQ ID NOs: 3 and 4 of the sequence listing, and a 3 ′ region detection primer consisting of the base sequences shown in SEQ ID NOs: 20 and 21, respectively. And a detection reagent for a fusion gene fused with an ALK gene.
- the present invention provides a novel method capable of comprehensively detecting fusion genes that can exist in a living body regardless of the type of fusion partner. According to the method of the present invention, it was possible to detect fusion genes with any fusion partner by measuring the expression level of only two gene regions, and it was necessary to detect various types of fusion genes. Time and cost can be greatly reduced.
- a fusion gene of the 3 ′ region containing the kinase domain of the ALK gene and the EML4 gene or the like is known as a fusion gene of the ALK gene.
- PCR can be performed in a single tube including the internal standard, which is extremely advantageous as a simple and rapid ALK fusion gene detection system.
- Fusion genes such as the EML4-ALK fusion gene, have been found in some cancer patients, and prescribe an inhibitor that inhibits the activity of the fusion gene product for such fusion gene-expressing patients This may be useful in the treatment of cancer.
- Example 1 H2228 cells (EML4-ALK fusion gene positive, ALK gene negative), A549 cells (EML4-ALK fusion gene negative, ALK gene negative), SK-N-DZ cells (EML4-ALK fusion gene negative, ALK) It is the result of having measured the expression of 5 'area
- Example 2 with respect to RNA samples extracted from H2228 cells, A549 cells, and SK-N-DZ cellularity, the 5 ′ region and 3 ′ region of the ALK gene and the internal standard gene TBP gene were simultaneously amplified and electrophoresed. is there.
- Example 3 for RNA samples extracted from H2228 cells, A549 cells, and SK-N-DZ cellularity, the 5 ′ region and 3 ′ region of the ALK gene and the internal standard gene TBP gene were simultaneously amplified, and the amplified product was fluorescent. It is the result measured by the probe.
- the fusion gene to be measured in the present invention means that a translocation (including inversion) occurs on the same chromosome or between different chromosomes, and a part of a certain gene is fused with a part of another gene. It exists as a gene. Normally, genes that should not be expressed in a certain tissue are expressed by fusing with the promoter region of other genes that can be expressed in that tissue as a result of chromosomal translocation, often resulting in various diseases such as cancer. Is known to produce Many of the known fusion genes have been identified as abnormal genes in connection with various diseases.
- One of the genes constituting the fusion gene to be measured in the present invention is usually a gene that normally does not express the full length in a normal tissue, but a partial region thereof can be expressed in the tissue by fusion, The expression of the 5 'region and 3' region of this gene is measured. However, even if the gene is expressed in full length in normal tissues, as described later, the presence or absence and expression level of the fusion gene can be examined by the ratio of the expression levels of the 5 ′ region and the 3 ′ region.
- the conditions for the fusion gene are not limited to the above.
- fusion genes include fusion genes of genes such as ALK gene, ABL gene, retinoic acid receptor gene, SSX gene, AML1 gene and other genes.
- ALK gene is a gene encoding a receptor tyrosine kinase, but various fusion genes in which the 3 ′ region containing the kinase domain is fused with the 5 ′ region of another gene are known, These are known to exhibit carcinogenicity (see Non-Patent Document 5, etc.).
- the scope of the present invention is not limited to these specific examples, and includes various natural fusion genes not related to diseases, in addition to fusion genes related to various diseases such as cancer.
- the ALK gene (SEQ ID NO: 1, GenBank NM_004304) is a gene consisting of 29 exons on human chromosome 2, and the kinase domain is 4256nt to 5083nt (meaning 4256th base to 5083th base) It is.
- Each exon region of the ALK gene shown in SEQ ID NO: 1 is shown in Table 1 below.
- fusion genes with various fusion partners are known as fusion genes of the ALK gene and other arbitrary genes (hereinafter sometimes simply referred to as “ALK fusion genes”). It has been. Examples of known ALK fusion genes are shown in SEQ ID NOs: 9 to 18 in the sequence listing.
- SEQ ID NOs: 9 to 17 are the base sequences of the EML4-ALK fusion gene
- SEQ ID NO: 18 is the base sequence of the KIF5B-ALK fusion gene.
- the exon 20-29 region including the kinase domain of the ALK gene is fused with the 5 ′ region including the promoter region of other genes, and in some non-small cell lung cancer patients, It is expressed.
- the method of the present invention attention is paid to only one gene constituting the fusion gene, and the expression at two locations, the 5 ′ region upstream and the 3 ′ region downstream from the fusion point of the gene, is measured.
- one gene constituting a fusion gene for which the 5 ′ region and the 3 ′ region are to be measured may be referred to as a “target gene” for convenience.
- “Measurement” includes detection, quantification, and semi-quantification.
- the “fusion point” refers to the boundary between the region lost by fusion and the region contained in the fusion gene, and in the fusion gene is the boundary where two different genes are fused. You can also.
- the 5 ′ end of exon 20 in the ALK gene that is, 4080 nt in SEQ ID NO: 1 is the fusion point.
- the 5 ′ region and 3 ′ region to be measured may be selected from regions upstream and downstream from the fusion point, respectively.
- the fusion point is not necessarily limited to only one point in the gene, and several tens of bases or more between variants of the same fusion gene consisting of the same gene combination. Its position can be different. Therefore, it is desirable to select the 5 ′ region to be measured from the region upstream of the fusion point that is the 5 ′ most of the known fusion points, and similarly for the 3 ′ region, Of these, it is desirable to select from the region downstream of the fusion point located on the most 3 ′ side. From the viewpoint of covering unknown variants that have not been specifically identified, a region sufficiently separated from the most upstream or downstream fusion point, for example, about 200 bases, preferably from a region separated by 500 bases or more. It is preferable to select.
- the known ALK fusion genes are fused to the fusion partner in exon 20 of the ALK gene and its downstream region. May be selected from exon 19 of the ALK gene and the upstream region thereof, and the 3 ′ region may be selected from exon 20 of the ALK gene and the downstream region thereof.
- the known ALK fusion genes there are those in which up to 49 bp of the 5 ′ end of exon 20 is lost (SEQ ID NO: 13). Therefore, 4129 nt (SEQ ID NO: 13) which is the fusion point of this variant The position is based on 1. It is desirable to select the 3 ′ region from the region downstream from the expression of the fusion point position.
- the 3 ′ region is a region sufficiently separated from the fusion point of 4129 nt, which is the most 3 ′ side of the known fusion points, for example, a region separated by about 200 bp or more, preferably about 500 bp or more. preferable.
- the 3 ′ region from the kinase domain of the ALK gene.
- the expression of the 2486nt to 2629nt region of SEQ ID NO: 1 as the 5 'region and the expression of the 4801nt to 4865nt or 4775nt to 4939nt region of SEQ ID NO: 1 as the 3' region are measured.
- the present invention is not limited to such specific examples.
- the sample used in the present invention is a protein sample or nucleic acid sample separated from a living body, preferably a nucleic acid sample.
- an RNA sample such as a total RNA sample extracted from a sample of cells, tissues, blood or the like collected from a living body is preferable.
- the RNA sample can be used after reverse transcription to cDNA.
- RNA extraction and cDNA synthesis are conventional methods known per se and can be easily performed using commercially available kits. It is desirable to use a random hexamer as a primer for the reverse transcription reaction.
- the measurement of the expression of the 5 ′ region and the 3 ′ region can be performed, for example, by immunoassaying a protein sample using an antibody that specifically recognizes the 5 ′ region and the 3 ′ region, respectively. Then, it is preferable to carry out by measuring the 5 ′ region and 3 ′ region of mRNA transcribed from the target gene or cDNA synthesized from this mRNA for the RNA sample.
- mRNA or cDNA measurement methods include a nucleic acid amplification method using primers and a hybridization method using probes.
- the nucleic acid amplification method include RT-PCR, real-time PCR, and NASBA method.
- hybridization methods include Northern blotting, in situ hybridization, array analysis methods using a solid phase probe, and the like. These methods are well-known ordinary methods, and any method may be used in the present invention.
- the immunoassay itself and a method for producing an antibody that specifically recognizes a desired region are also well-known conventional methods.
- a polynucleotide that specifically hybridizes to each of the 5 ′ region and 3 ′ region of interest is used.
- “specifically hybridizes” means that it hybridizes only with the target mRNA or cDNA under normal hybridization conditions and does not substantially hybridize with other nucleic acids.
- Normal hybridization conditions refer to conditions used for normal PCR annealing and probe detection. For example, in the case of PCR using Taq polymerase, 50 mM KCl, 10 mM Tris-HCl ( The reaction is performed at a suitable annealing temperature of about 54 ° C. to 60 ° C. using a general buffer solution such as pH 8.3 to 9.0) and 1.5 mM MgCl 2.
- the reaction is performed at a suitable hybridization temperature of about 42 ° C. to 65 ° C. using a general hybridization solution such as 5 ⁇ SSPE, 50% formamide, 5 ⁇ Denhardt's solution, and 0.1 to 0.5% SDS.
- a general hybridization solution such as 5 ⁇ SSPE, 50% formamide, 5 ⁇ Denhardt's solution, and 0.1 to 0.5% SDS.
- the appropriate annealing temperature or hybridization temperature is not limited to the above examples, and is determined based on the Tm value of the polynucleotide used as the primer or probe and the rule of thumb of the experimenter, and can be easily determined by those skilled in the art. Can do.
- substantially does not hybridize means that it does not hybridize at all, or even if it is significantly less than the amount hybridized to the target region, and hybridizes only in a relatively negligible amount. is there.
- a polynucleotide can be appropriately designed and prepared by those skilled in the art with reference to known sequence information. Sequence information can be easily obtained from databases such as GenBank. For example, in the case of the base sequence of the ALK gene, it is registered in GenBank with accession number NM_004304, and is also described as SEQ ID NO: 1 in the present sequence listing.
- RT-PCR and real-time PCR include the methods described in the following examples.
- primers that specifically amplify the 5 'region and 3' region of the target gene such as ALK gene using the cDNA as a template
- the expression of each region of the target gene can be measured.
- real-time PCR a detection method using a fluorescently labeled probe is also known, and it is possible to perform simpler and quicker detection by omitting the amplification product migration step.
- a fluorescently labeled probe that specifically hybridizes to the amplified fragment of each region can be prepared and used.
- amplification fragments can be distinguished and measured according to the fluorescence wavelength.
- a fluorescently labeled probe can be easily prepared by those skilled in the art, and specific examples thereof are described in the following examples.
- “specifically amplify” means to amplify only the target region or a non-target region, but it is very small compared to the amount of amplification in the target region and can be relatively ignored. It means that it only amplifies.
- the set of primers that specifically hybridize within the 5 ′ region is a primer set that specifically amplifies the 5 ′ region. A person skilled in the art can appropriately select the size to be amplified.
- the primer set when the target gene is the ALK gene, specific examples of the primer set include the primer set shown in SEQ ID NOs: 3 and 4 and the 3 ′ region specifically amplified as the primer set that specifically amplifies the 5 ′ region. Examples of the primer set include, but are not limited to, the primer sets shown in SEQ ID NOs: 5 and 6, or the primer sets shown in SEQ ID NO: 20 and SEQ ID NO: 21.
- an ALK5 ′ region-specific probe consisting of the base sequence shown in SEQ ID NO: 19 that can be used in combination with the primer set of SEQ ID NOs: 3 and 4, and a primer set of SEQ ID NOs: 20 and 21 are used.
- an ALK3 ′ region-specific probe consisting of the base sequence shown in SEQ ID NO: 22 that can be used, but is not limited thereto.
- one or more types of internal standard genes may be measured.
- the internal standard gene GAPDH gene, ACTB gene, HPRT1 gene, HMBS gene, TBP gene and the like are well known, and these can also be used in the present invention.
- a fluorescently labeled probe can also be prepared and used for the internal standard gene.
- the TBP gene is used as an internal standard, and the base sequence of the primer set therefor is shown in SEQ ID NOs: 7 and 8 or SEQ ID NOs: 23 and 24, but is not limited thereto.
- Specific examples of the TBP gene-specific probe include, but are not limited to, a probe comprising the base sequence shown in SEQ ID NO: 25 that can be used in combination with the primer set of SEQ ID NOs: 23 and 24.
- the expression of each region is compared.
- the expression level of each region of the target gene normalized by the expression level of the internal standard gene may be compared.
- the amplification product is confirmed by electrophoresis, the presence or absence of a band or the signal intensity may be compared.
- the full length of the target gene is expressed in the biological tissue or cell from which the sample is derived, the expression of both the 5 ′ region and the 3 ′ region is confirmed.
- the expression of the 5 ′ region is not confirmed, and only the expression of the 3 ′ region is confirmed.
- the expression of the fusion gene can be confirmed in more detail.
- a control sample can be easily prepared by a person skilled in the art based on known information.
- cell lines such as SK-N-DZ cells are known as cell lines that express only the full length of the ALK gene and do not express the ALK fusion gene.
- the expression of the fusion gene can be measured based on the presence or absence of the expression of the 5 ′ region and 3 ′ region of the target gene or the ratio of the expression level.
- the full length of the ALK gene is not expressed in human lung, it is known that the ALK fusion gene is expressed in lung cancer cells in some non-small cell lung cancer patients. Therefore, when the method of the present invention is performed using an RNA sample extracted from a lung biopsy sample collected from a lung cancer patient, the expression of the fusion gene can be detected based on the presence or absence of the expression of the 5 ′ region. That is, in this case, it can be determined that the ALK fusion gene is present and expressed in a patient in which only the 3 ′ region is expressed and the 5 ′ region is not expressed.
- the ALK fusion gene can be detected based on the presence or absence of the 5 ′ region and 3 ′ region or the ratio thereof.
- the formulation of an ALK inhibitor is useful for the treatment of cancer, and by using the method of the present invention, it is possible to select a patient to be prescribed for an ALK inhibitor.
- the method of the present invention is not limited to lung cancer, and the ALK fusion gene is known to be associated with various cancers, and prescriptions of ALK inhibitors are useful for various cancers other than lung cancer. Is equally useful.
- ALK fusion genes there are genes that are known to be associated with cancer, and similarly, it is known that inhibitor prescriptions are useful for cancer treatment. It is equally useful for cancers associated with these fusion genes.
- the primer set is particularly useful as a detection reagent for ALK fusion genes.
- the reagent may be composed of only a primer, or may contain various additives useful for stabilizing the primer.
- the reagent may further include an internal standard primer set.
- the reagent may further contain a fluorescently labeled probe for real-time PCR. The conditions for the primer set and the fluorescently labeled probe are as described above.
- RNA samples 1 Cell density of 20000 cells / cm 2 for H2228 cells (human lung cancer-derived cell line, ATCC), A549 cells (human lung cancer-derived cell line, ATCC), and SK-N-DZ cells (human neuroblastoma-derived cell line, ECACC) Inoculated into a culture container of a 6-well culture plate so that the sample was cultured for 2 days.
- RNA extraction from the sample was performed according to the manual using a commercially available RNA extraction kit (Rneasy mini kit, Qiagen) to obtain an RNA sample.
- the extracted RNA sample was reverse transcribed to DNA with RT primer (random hexamer, Invitrogen) and Super Script II reverse transcriptase (Invitrogen) to obtain a cDNA sample.
- RT primer random hexamer, Invitrogen
- Super Script II reverse transcriptase Invitrogen
- the TBP gene was measured by real-time PCR using SYBR Green Realtime PCR Master Mix -Plus- (manufactured by Toyobo Co., Ltd.) as the 5 ′ region and 3 ′ region of the ALK gene contained in this cDNA sample and the internal standard gene.
- the following primers were used.
- the reaction conditions were 96 ° C. for 120 seconds and then 96 ° C. for 10 seconds—annealing 60 ° C. for 30 seconds—extension 72 ° C. for 30 seconds.
- the number of cycles was determined appropriately by monitoring real-time PCR.
- the following primers were used.
- the composition of the reaction solution was such that each primer was used at a concentration of 0.8 ⁇ M, and the buffer attached to the kit was used according to the attached instructions.
- ALK5 'area Forward (cccgcttctgaaagtgctac, SEQ ID NO: 3), reverse (cccggttttgttctccacta, SEQ ID NO: 4)
- ALK3 'area Forward (agaggccttcatggaaggaa, SEQ ID NO: 5), reverse (atagcagcactccaaaggac, SEQ ID NO: 6)
- TBP gene Forward (ccaaggaattgaggaagttgc, SEQ ID NO: 7), reverse (gtgccataaggcatcattgg, SEQ ID NO: 8)
- Example 2 RNA sample preparation and analysis 2 Similar to Example 1, cDNA samples derived from each cell were obtained. Amplified and electrophoresed by the multiplex PCR method using TITANIUM Taq DNA polymerase (manufactured by TAKARA BIO INC.) As the 5 'region and 3' region of the ALK gene contained in this cDNA sample and the TBP gene as an internal standard gene did. The same primer as in Example 1 was used. The PCR reaction conditions were heat denaturation at 96 ° C. for 120 seconds, followed by 35 cycles of 96 ° C. for 15 seconds to 68 ° C. for 60 seconds. The composition of the reaction solution was such that each primer was used at a concentration of 0.8 ⁇ M, and a buffer attached to the polymerase was used according to the attached instructions.
- Example 3 In the same manner as in Example 1, RNA samples derived from each cell were obtained. In the one-step real-time PCR method using TITANIUM One-Step RT-PCR Kit (manufactured by TAKARA BIO INC.) With the TBP gene as the 5 'region and 3' region of the ALK gene contained in this RNA sample and the internal standard gene It was measured. The following were used as the primers and probes for specifically detecting each amplification product. Each probe is labeled with a fluorescent substance having three different wavelengths at the 3 ′ end, and the abundance of the amplification product can be measured by a known fluorescence quenching reaction with a guanine base.
- the reaction conditions were 50 ° C for 1 hour, heat denaturation at 96 ° C for 120 seconds, 96 ° C for 10 seconds-annealing at 60 ° C for 30 seconds-extension at 72 ° C for 30 seconds, and the number of cycles was determined appropriately by monitoring real-time PCR. .
- the composition of the reaction solution was such that each primer was used at a concentration of 0.8 ⁇ M and each probe was used at a concentration of 0.1 ⁇ M, and a buffer attached to the kit was used according to the attached instructions.
- ALK5 'area Forward (cccgcttctgaaagtgctac, SEQ ID NO: 3), reverse (cccggttttgttctccacta, SEQ ID NO: 4), probe (tctccatgtgagctccgaatgtcc, TAMRA modification at the 3 ′ end cytosine base, SEQ ID NO: 19)
- TBP gene Forward (cttggcgtgtgaagataacc, SEQ ID NO: 23), reverse (tgctgcctttg
Abstract
Description
H2228細胞(ヒト肺癌由来細胞株、ATCC)、A549細胞(ヒト肺癌由来細胞株、ATCC)、SK-N-DZ細胞(ヒト神経芽腫由来細胞株、ECACC)を20000細胞/cm2の細胞密度となるように6穴培養プレートの培養容器に播種し、2日間培養してサンプルとした。サンプルからのRNA抽出は、市販のRNA抽出キット(Rneasy mini kit、キアゲン社)を用いてマニュアルに従い実施し、RNAサンプルを得た。抽出したRNAサンプルをRTプライマー(ランダムヘキサマー、インビトロジェン社)およびSuper Script II逆転写酵素(インビトロジェン社製)にてDNAに逆転写し、cDNAサンプルを得た。
ALK5'領域:
フォワード(cccgcttctgaaagtgctac、配列番号3)、リバース(cccggttttgttctccacta、配列番号4)
ALK3'領域:
フォワード(agaggccttcatggaaggaa、配列番号5)、リバース(atagcagcactccaaaggac、配列番号6)
TBP遺伝子:
フォワード(ccaaggaattgaggaagttgc、配列番号7)、リバース(gtgccataaggcatcattgg、配列番号8)
実施例1と同様に各細胞由来のcDNAサンプルを得た。このcDNAサンプル中に含まれるALK遺伝子の5'領域、3'領域および内部標準遺伝子としてTBP遺伝子をTITANIUM Taq DNA polymerase(タカラバイオ社製)を使用したマルチプレックスPCR法にて増幅、電気泳動を実施した。プライマーは実施例1と同様のものを使用した。PCRの反応条件は、96℃120秒の熱変性後、96℃15秒-68℃60秒を35サイクルとした。反応液の組成は、各プライマーを0.8μMの濃度で使用した他は、ポリメラーゼに添付のバッファー等を添付の指示書に従って用いた。
実施例1と同様に各細胞由来のRNAサンプルを得た。このRNAサンプル中に含まれるALK遺伝子の5'領域、3'領域および内部標準遺伝子としてTBP遺伝子をTITANIUM One-Step RT-PCR Kit(タカラバイオ社製)を使用したOne-Step リアルタイムPCR法にて測定した。プライマーおよび各増幅産物を特異的に検出するプローブは以下のものを使用した。各プローブは、それぞれ3'末端に異なる3波長を有した蛍光物質が標識されており、公知であるグアニン塩基による蛍光消光反応により、増幅産物の存在量を測定可能である。反応条件は、50℃ 1時間、96℃120秒の熱変性後、96℃10秒-アニーリング60℃30秒-伸長72℃30秒のサイクルとし、サイクル数はリアルタイムPCRをモニターして適宜決定した。反応液の組成は、各プライマーを0.8μM、各プローブを0.1μMの濃度で使用した他は、キットに添付のバッファー等を添付の指示書に従って用いた。
ALK5'領域:
フォワード(cccgcttctgaaagtgctac、配列番号3)、リバース(cccggttttgttctccacta、配列番号4)、プローブ(tctccatgtgagctccgaatgtcc、3'末端のシトシン塩基にTAMRA修飾、配列番号19)
ALK3'領域:
フォワード(atgctgccagttaagtggatg、配列番号20)、リバース(actggtgacaaactccagaac、配列番号21)、プローブ(tatgccataccccagcaaaagcaac、3'末端のシトシン塩基にBODIPY FL修飾、配列番号22)
TBP遺伝子:
フォワード(cttggcgtgtgaagataacc、配列番号23)、リバース(tgctgcctttgttgctcttc、配列番号24)、プローブ(ccttacgctcagggcttggcctcc、3'末端のシトシン塩基に5-CR6G修飾、配列番号25)
Claims (14)
- 生体から分離された試料に対して行なう方法であって、該生体内に存在し得る融合遺伝子を構成する一方の遺伝子について、遺伝子の融合点よりも上流の5'領域及び下流の3'領域の発現をそれぞれ測定し、5'領域の発現と3'領域の発現とを対比することを含む、融合遺伝子の測定方法。
- 融合遺伝子を構成する前記一方の遺伝子がALK遺伝子である請求項1記載の方法。
- 前記5'領域がALK遺伝子のエクソン1~19内のいずれかの領域であり、前記3'領域がエクソン20~29内のいずれかの領域である請求項2記載の方法。
- 前記5'領域は、配列番号1に示すALK遺伝子配列の1nt~4079ntの領域内のいずれかの領域であり、前記3'領域はALK遺伝子配列の4129nt~6222ntの領域内のいずれかの領域である請求項3記載の方法。
- 前記試料がRNA試料であり、前記発現の測定は、ALK遺伝子から転写されたmRNA又はこれから合成されたcDNAの5'領域及び3'領域を測定することにより行なわれる請求項1ないし4のいずれか1項に記載の方法。
- 5'領域を特異的に増幅するプライマーセットと、3'領域を特異的に増幅するプライマーセットとを用いたRT-PCRにより行なわれる請求項5記載の方法。
- 配列表の配列番号3及び4にそれぞれ示される塩基配列から成る5'領域検出用プライマーセットと、配列番号5及び6にそれぞれ示される塩基配列から成る3'領域検出用プライマーセットとを用いる請求項6記載の方法。
- 配列番号7及び8にそれぞれ示される塩基配列から成る内部標準用プライマーセットをさらに用いる請求項7記載の方法。
- 前記生体ががん患者である請求項2ないし8のいずれか1項に記載の方法。
- 前記生体が肺癌患者である請求項9記載の方法。
- 配列表の配列番号3及び4にそれぞれ示される塩基配列から成る5'領域検出用プライマーセットと、配列番号5及び6にそれぞれ示される塩基配列から成る3'領域検出用プライマーセットとを含む、ALK遺伝子と融合した融合遺伝子の検出試薬。
- 配列表の配列番号3及び4にそれぞれ示される塩基配列から成る5'領域検出用プライマーセットと、配列番号20及び21にそれぞれ示される塩基配列から成る3'領域検出用プライマーセットとを含む、ALK遺伝子と融合した融合遺伝子の検出試薬。
- 配列番号7及び8にそれぞれ示される塩基配列から成る内部標準用プライマーセットをさらに含む請求項11記載の試薬。
- 配列番号23及び24にそれぞれ示される塩基配列から成る内部標準用プライマーセットをさらに含む請求項12記載の試薬。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/500,497 US20120202214A1 (en) | 2009-10-06 | 2010-09-28 | Method for detecting fusion gene |
EP10821891A EP2487250A4 (en) | 2009-10-06 | 2010-09-28 | METHOD FOR DETECTION OF A FUSION GENE |
JP2011535352A JPWO2011043220A1 (ja) | 2009-10-06 | 2010-09-28 | 融合遺伝子の測定方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-232473 | 2009-10-06 | ||
JP2009232473 | 2009-10-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011043220A1 true WO2011043220A1 (ja) | 2011-04-14 |
Family
ID=43856678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/066768 WO2011043220A1 (ja) | 2009-10-06 | 2010-09-28 | 融合遺伝子の測定方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20120202214A1 (ja) |
EP (1) | EP2487250A4 (ja) |
JP (1) | JPWO2011043220A1 (ja) |
WO (1) | WO2011043220A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013065646A1 (ja) | 2011-10-31 | 2013-05-10 | アークレイ株式会社 | 遺伝子存在量の測定方法 |
US8962245B2 (en) | 2010-09-02 | 2015-02-24 | Kurume University | Method for producing circular DNA formed from single-molecule DNA |
WO2015064620A1 (ja) * | 2013-10-29 | 2015-05-07 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
WO2015064621A1 (ja) * | 2013-10-29 | 2015-05-07 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
US9121051B2 (en) | 2011-10-31 | 2015-09-01 | Arkray, Inc. | Method of determining the abundance of a target nucleotide sequence of a gene of interest |
US9416358B2 (en) | 2011-08-31 | 2016-08-16 | Kurume University | Method for exclusive selection of circularized DNA from monomolecular DNA in circularizing DNA molecules |
US10294515B2 (en) | 2011-07-01 | 2019-05-21 | Htg Molecular Diagnostics, Inc. | Methods of detecting gene fusions |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3133168B1 (en) | 2009-05-26 | 2019-01-23 | Quest Diagnostics Investments Incorporated | Methods for detecting gene dysregulations |
CN106462669A (zh) * | 2014-03-25 | 2017-02-22 | 奎斯特诊断投资股份有限公司 | 通过使用平均循环阈值的基因内差异表达(ide)检测基因融合 |
JP6856544B2 (ja) * | 2015-04-17 | 2021-04-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 遺伝子融合体を検出するための多重pcr |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10215897A (ja) * | 1997-02-05 | 1998-08-18 | Bunshi Bio Photonics Kenkyusho:Kk | 染色体相互転座による変異細胞検出方法、その検出用プローブキット、およびその検出装置 |
WO2002093130A2 (en) * | 2001-05-14 | 2002-11-21 | Cancer Genetics, Inc. | Methods of analyzing chromosomal translocations using fluorescence in situ hybridization (fish) |
JP2004089089A (ja) * | 2002-08-30 | 2004-03-25 | Srl Inc | PML−RARAキメラmRNA測定用核酸及びそれを用いたPML−RARAキメラmRNAの測定方法 |
JP2007535966A (ja) * | 2004-05-04 | 2007-12-13 | ダコ デンマーク アクティーゼルスカブ | 染色体異常を検出するための方法 |
JP2008295444A (ja) | 2006-10-11 | 2008-12-11 | Astellas Pharma Inc | Eml4−alk融合遺伝子 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5529925A (en) * | 1993-12-03 | 1996-06-25 | St. Jude Children's Research Hospital | Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma |
SI2450437T1 (sl) * | 2006-04-14 | 2017-12-29 | Cell Signaling Technology Inc. | Okvarjenost genov in mutantna ALK kinaza v človeških solidnih tumorjih |
EP1914240B1 (en) * | 2006-10-11 | 2009-12-02 | Astellas Pharma Inc. | EML4-ALK fusion gene |
EP3133168B1 (en) * | 2009-05-26 | 2019-01-23 | Quest Diagnostics Investments Incorporated | Methods for detecting gene dysregulations |
-
2010
- 2010-09-28 EP EP10821891A patent/EP2487250A4/en not_active Withdrawn
- 2010-09-28 JP JP2011535352A patent/JPWO2011043220A1/ja not_active Withdrawn
- 2010-09-28 US US13/500,497 patent/US20120202214A1/en not_active Abandoned
- 2010-09-28 WO PCT/JP2010/066768 patent/WO2011043220A1/ja active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10215897A (ja) * | 1997-02-05 | 1998-08-18 | Bunshi Bio Photonics Kenkyusho:Kk | 染色体相互転座による変異細胞検出方法、その検出用プローブキット、およびその検出装置 |
WO2002093130A2 (en) * | 2001-05-14 | 2002-11-21 | Cancer Genetics, Inc. | Methods of analyzing chromosomal translocations using fluorescence in situ hybridization (fish) |
JP2004089089A (ja) * | 2002-08-30 | 2004-03-25 | Srl Inc | PML−RARAキメラmRNA測定用核酸及びそれを用いたPML−RARAキメラmRNAの測定方法 |
JP2007535966A (ja) * | 2004-05-04 | 2007-12-13 | ダコ デンマーク アクティーゼルスカブ | 染色体異常を検出するための方法 |
JP2008295444A (ja) | 2006-10-11 | 2008-12-11 | Astellas Pharma Inc | Eml4−alk融合遺伝子 |
Non-Patent Citations (6)
Title |
---|
BIOCHEM. J., vol. 420, 2009, pages 345 - 361 |
CLIN. CAN. RES., vol. 14, 2008, pages 6618 - 6624 |
CLIN. CAN. RES., vol. 15, 2009, pages 3143 - 3149 |
HIROYUKI MANO: "Haigan no Atarashii Gan Idenshi -EML4-ALK Yugo Idenshi", THE LUNG PERSPECTIVES, vol. 16, no. 4, 2008, pages 76 - 78, XP008161091 * |
J. CLIN. ONCOL., vol. 27, 2009, pages 1 - 4 |
NATURE, vol. 448, 2007, pages 561 - 566 |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8962245B2 (en) | 2010-09-02 | 2015-02-24 | Kurume University | Method for producing circular DNA formed from single-molecule DNA |
US9434941B2 (en) | 2010-09-02 | 2016-09-06 | Kurume University | Method for producing circular DNA formed from single-molecule DNA |
US11268133B2 (en) | 2011-07-01 | 2022-03-08 | Htg Molecular Diagnostics, Inc. | Methods of detecting gene fusions |
US10294515B2 (en) | 2011-07-01 | 2019-05-21 | Htg Molecular Diagnostics, Inc. | Methods of detecting gene fusions |
US9416358B2 (en) | 2011-08-31 | 2016-08-16 | Kurume University | Method for exclusive selection of circularized DNA from monomolecular DNA in circularizing DNA molecules |
US9121051B2 (en) | 2011-10-31 | 2015-09-01 | Arkray, Inc. | Method of determining the abundance of a target nucleotide sequence of a gene of interest |
WO2013065646A1 (ja) | 2011-10-31 | 2013-05-10 | アークレイ株式会社 | 遺伝子存在量の測定方法 |
KR101483576B1 (ko) | 2011-10-31 | 2015-01-21 | 아크레이 가부시키가이샤 | 유전자 존재량의 측정 방법 |
JP5570657B2 (ja) * | 2011-10-31 | 2014-08-13 | アークレイ株式会社 | 遺伝子存在量の測定方法 |
WO2015064621A1 (ja) * | 2013-10-29 | 2015-05-07 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
WO2015064620A1 (ja) * | 2013-10-29 | 2015-05-07 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
JPWO2015064621A1 (ja) * | 2013-10-29 | 2017-03-09 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
JPWO2015064620A1 (ja) * | 2013-10-29 | 2017-03-09 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
Also Published As
Publication number | Publication date |
---|---|
EP2487250A1 (en) | 2012-08-15 |
EP2487250A4 (en) | 2013-03-20 |
JPWO2011043220A1 (ja) | 2013-03-04 |
US20120202214A1 (en) | 2012-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011043220A1 (ja) | 融合遺伝子の測定方法 | |
JP6100685B2 (ja) | 血中dnaの定量的検出による悪性新生物の病勢の進行を評価する方法 | |
Gunduz et al. | Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas | |
US9216172B2 (en) | Method for determining effectiveness of cancer treatment by assessing the presence of a KIF5B-RET chimeric gene | |
JP5769952B2 (ja) | Eml4−alk融合遺伝子の高感度検出方法 | |
JP2017538404A (ja) | 癌を診断及び/又は観察するための循環無細胞rnaの使用 | |
AU2013281355B2 (en) | Targeted RNA-seq methods and materials for the diagnosis of prostate cancer | |
JP7392048B2 (ja) | 分析方法及びキット | |
CN110863053A (zh) | 一种检测EGFR vIII突变体的引物、探针及方法 | |
Robesova et al. | TaqMan based real time PCR assay targeting EML4-ALK fusion transcripts in NSCLC | |
Araki et al. | Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon12 mutations in lung adenocarcinoma: Comparison of PNA-clamp SmartAmp2 and PCR-related methods | |
JP2017169580A (ja) | 上皮増殖因子受容体キナーゼ・ドメイン内の新規な複合突然変異 | |
Wong et al. | The role of microsatellite instability in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix | |
Feng et al. | Reduced telomere length in colorectal carcinomas | |
US9029089B2 (en) | Methods for predicting survival in cancer patients | |
KR20100034557A (ko) | 폐선암 수술 후 초기 재발 예측용 바이오마커 | |
JP7297902B2 (ja) | 分析方法及びキット | |
JP6806440B2 (ja) | 新規融合体及びその検出法 | |
JP7346533B2 (ja) | 分析方法及びキット | |
WO2013075110A2 (en) | A novel eml4-alk variant: primers, probes, methods, and kits for the detection thereof | |
Baum et al. | Non-small cell lung carcinoma: molecular genetics with consideration of cytologic samples | |
Vlastos et al. | Mapping EGFR1 mutations in patients with lung adenocarcinoma | |
CA2641410A1 (en) | Genes for prognosis of cancer | |
US20140093872A1 (en) | Method of Mutation Detection in Blood Cell-Free DNA Using Primer Extension (PE) and PCR | |
EP3146073B1 (en) | A diagnostic marker for paget disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10821891 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011535352 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13500497 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2010821891 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010821891 Country of ref document: EP |